within Pharmacolibrary.Drugs.ATC.B;

model B01AD07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 224 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.0128,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Reteplase is a recombinant tissue plasminogen activator (rtPA) used as a thrombolytic agent for the treatment of acute myocardial infarction (AMI). It works by dissolving blood clots and restoring blood flow in blocked coronary arteries. Reteplase is approved for medical use in many countries and has largely been replaced by more recently developed thrombolytic agents in some settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with acute myocardial infarction, both male and female, after intravenous bolus injection.</p><h4>References</h4><ol><li><p>Ware, JH, &amp; Antman, EM (1997). Equivalence trials. <i>The New England journal of medicine</i> 337(16) 1159–1161. DOI:<a href=&quot;https://doi.org/10.1056/NEJM199710163371610&quot;>10.1056/NEJM199710163371610</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9329939/&quot;>https://pubmed.ncbi.nlm.nih.gov/9329939</a></p></li><li><p>Noble, S, &amp; McTavish, D (1996). Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. <i>Drugs</i> 52(4) 589–605. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199652040-00012&quot;>10.2165/00003495-199652040-00012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8891469/&quot;>https://pubmed.ncbi.nlm.nih.gov/8891469</a></p></li><li><p>Martin, U, et al., &amp; Neugebauer, G (1999). Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective. <i>Clinical pharmacokinetics</i> 36(4) 265–276. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936040-00002&quot;>10.2165/00003088-199936040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10320949/&quot;>https://pubmed.ncbi.nlm.nih.gov/10320949</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AD07;
